8-K Announcements
6Material company update
May 29, 2026·SEC
Material company update
May 26, 2026·SEC
Material company update
May 18, 2026·SEC
Silexion Therapeutics Ltd.(SLXNW)Earnings, Financials & Key Ratios
SLXNW•NASDAQ
$0.03
Price updated Jun 27, 2026
AboutSilexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.Show more
- Revenue$0
- EBITDA$12M+192.8%
- Net Income-$12M+27.6%
- EPS (Diluted)-89.60-239.4%
- ROE-457.63%
SLXNW Price & Volume
Silexion Therapeutics Ltd. (SLXNW) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Capital Structure Stability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent capital depletion risk
Key Thesis Takeaways
- Silexion Therapeutics remains a high-risk, pre-revenue clinical-stage entity characterized by an aggressive cash burn rate that consistently outpaces its limited liquidity.
- While the company advances its LODER delivery platform, the lack of commercial revenue and the accumulation of $57.9 million in historical losses necessitate frequent external financing.
- Investors should remain cautious as the current $2.4 million cash position provides a narrow runway that may force dilutive equity raises to sustain ongoing research operations.
Verdict Logic
the company's precarious financial position, highlighted by a current ratio of 1.00 and a rapid erosion of total assets from $11.6 million to $4.6 million in just two quarters, suggests an imminent risk of severe shareholder dilution.
SLXNW Growth Metrics
Silexion Therapeutics Ltd. (SLXNW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.44%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM403.07%
Return on Capital
10 Years-120.92%
5 Years-105.93%
3 Years-173.9%
Last Year612.69%
SLXNW Recent Earnings
Silexion Therapeutics Ltd. (SLXNW) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/6 qtrs (67%)
Q2 2026Latest
May 18, 2026Metric
Actual
Est
EPS
$0.85+34.1%
$1.29
Rev
—
—
Q2 2026
May 15, 2026Metric
Actual
Est
EPS
$0.85+165.9%
$1.29
Rev
—
—
Q2 2026
Mar 17, 2026Metric
Actual
Est
EPS
$2.38-112.9%
$1.12
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$2.88+15.3%
$3.40
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 18, 2026 | $0.85vs $1.29+34.1% | — |
| Q2 2026 | May 15, 2026 | $0.85vs $1.29+165.9% | — |
| Q2 2026 | Mar 17, 2026 | $2.38vs $1.12-112.9% | — |
| Q4 2025 | Nov 12, 2025 | $2.88vs $3.40+15.3% | — |
Based on last 6 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Silexion Therapeutics Ltd. (SLXNW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.03 | $9.88K | -0.00 | — | — | -457.63% | — | |
| $16.85 | $1.78B | -2.36 | 15.58% | 2.98% | 4.89% | — | |
| $78.89 | $11.11B | -6466.39 | 23258.15% | -48.38% | -55.09% | — | |
| $67.27 | $26.68B | -9.27 | -39.23% | -143.55% | -36.73% | — | |
| $16.68 | $1.87B | -4.38 | 16.92% | -597.04% | -57.27% | — | |
| $34.81 | $3.58B | -42.98 | 120.01% | -49.17% | -5.89% | — |
Compare SLXNW vs Peers
Silexion Therapeutics Ltd. (SLXNW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SLXNW SEC Filings & Documents
Silexion Therapeutics Ltd. (SLXNW) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SLXNW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SLXNW Frequently Asked Questions
Silexion Therapeutics Ltd. (SLXNW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is SLXNW profitable?
Silexion Therapeutics Ltd. (SLXNW) reported a net loss of $12.9M for fiscal year 2025.
Dividend & Returns
What is SLXNW's return on equity?
Silexion Therapeutics Ltd. (SLXNW) has a return on equity (ROE) of -457.6%. Negative ROE indicates the company is unprofitable.
What is Silexion Therapeutics Ltd.'s free cash flow?
Silexion Therapeutics Ltd. (SLXNW) had negative free cash flow of $12.0M in fiscal year 2025, likely due to heavy capital investments.